Table 2.
Multivariable conditional analyses: odds ratio (OR) and 95% confidence interval (CI) for individual immune marker (categorical variable) and B-cell lymphoma and histological subtypes.
| Marker’s level |
BCL | CLL | FL | DLBCL | |||||
|---|---|---|---|---|---|---|---|---|---|
| N | OR (95% CI) | N | OR (95% CI) | N | OR (95% CI) | N | OR (95% CI) | ||
| sCD23, pg/mL | |||||||||
| Q1 | 6.345–7.45 | 63/130 | Ref | 16/54 | Ref | 20/27 | Ref | 27/49 | Ref |
| Q2 | 7.451–7.72 | 75/128 | 1.5 (0.95–2.38) | 19/48 | 1.22 (0.43–2.9) | 24/42 | 0.77 (0.3–1.89) | 32/38 | 1.86 (0.85–4.1) |
| Q3 | 7.721–7.972 | 104/128 | 1.9 (1.25–2.98) | 33/51 | 2.34 (1.03–5.3) | 34/33 | 1.57 (0.7–3.46) | 37/44 | 1.56 (0.7–3.39) |
| Q4 | 7.973–9.879 | 274/130 | 6.2 (3.95–9.74) | 142/57 | 10.5 (4.7–23.4) | 54/30 | 3.88 (1.54–9.8) | 78/43 | 4.10 (1.82–9.2) |
| P | 516/516 | < 0.0001 | 210/210 | < 0.0001 | 132/132 | 0.001 | 174/174 | 0.001 | |
| sCD30, ng/ml | |||||||||
| Q1 | 1.555–2.434 | 98/129 | Ref | 37/45 | Ref | 31/40 | Ref | 30/44 | Ref |
| Q2 | 2.435–2.639 | 96/128 | 1.11 (0.74–1.66) | 39/52 | 1.1 (0.49–2.20) | 19/34 | 0.92 (0.4–2.02) | 38/42 | 2.6 (1.15–5.91) |
| Q3 | 2.640–2.856 | 122/132 | 1.36 (0.91–2.06) | 52/54 | 1.42 (0.71–2.8) | 27/26 | 1.56 (0.66–3.6) | 43/52 | 1.99 (0.87–4.6) |
| Q4 | 2.857–5.621 | 200/127 | 2.62 (1.71–3.95) | 82/59 | 2.14 (1.1–4.24) | 55/32 | 3.0 (1.39–6.53) | 63/36 | 5.87 (2.4–14.7) |
| P | 516/516 | < 0.0001 | 210/210 | 0.01 | 132/132 | 0.003 | 174/174 | 0.001 | |
| sCD27, U/ml | |||||||||
| Q1 | 2.152–3.27 | 91/128 | Ref | 35/49 | Ref | 24/31 | Ref | 32/48 | Ref |
| Q2 | 3.271–3.459 | 100/126 | 1.38 (0.89–2.1) | 36/53 | 1.14 (0.56–2.3) | 29/37 | 1.15 (0.45–2.85) | 35/36 | 1.87 (0.86–4.1) |
| Q3 | 3.46–3.645 | 125/131 | 2.0 (1.25–3.19) | 51/51 | 2.1 (0.98–4.5) | 28/33 | 1.7 (0.61–4.74) | 46/47 | 1.98 (0.85–4.6) |
| Q4 | 3.646–5.707 | 195/126 | 4.24 (2.56–7.0) | 85/54 | 4.63 (2.0–10.7) | 50/30 | 4.29 (1.46–12.7) | 60/42 | 4.32 (1.7–10.9) |
| P | 511/511 | < 0.0001 | 207/207 | < 0.0001 | 131/131 | 0.004 | 173/173 | 0.003 | |
| CXCL13, pg/mL | |||||||||
| Q1 | 1.116–2.785 | 96/129 | Ref | 52/55 | Ref | 21/31 | Ref | 23/43 | Ref |
| Q2 | 2.786–3.086 | 94/127 | 1.2 (0.81–1.84) | 44/57 | 0.9 (0.46–1.75) | 25/36 | 1.11 (0.49–2.5) | 25/34 | 1.93 (0.84–4.4) |
| Q3 | 3.087–3.444 | 113/125 | 1.45 (0.95–2.2) | 45/39 | 1.35 (0.7–2.75) | 20/32 | 1.02 (0.4–2.58) | 48/54 | 2.15 (1.0–4.62) |
| Q4 | 3.445–6.809 | 203/125 | 2.6 (1.74–3.94) | 63/53 | 1.39 (0.7–2.7) | 62/29 | 4.01 (1.7–9.37) | 78/43 | 4.67 (2.14–10) |
| P | 506/506 | < 0.0001 | 204/204 | 0.17 | 128/128 | 0.0004 | 174/174 | < 0.0001 | |
B-cell lymphoma (BCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL); number of cases/controls (N); adjusted for BMI, education, smoking, alcohol intake, and physical activity; Quartiles were calculated based on the distribution in control subjects; tests for trend (p) were calculated using the quartile number as a continuous variable. Bold: statistically significant at p-value ≤ 0.05.